Literature DB >> 2867396

Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease.

R Clancy, A Cripps, K Murree-Allen, S Yeung, M Engel.   

Abstract

Fifty patients with chronic obstructive lung disease were randomly allocated to three groups, to assess whether an oral vaccine containing non-typable Haemophilus influenzae protected against acute bronchitis. The double-blind prospective study over a three-month winter period included two placebo groups and one test group. Oral immunisation with H influenzae induced a tenfold reduction in the incidence of infection (p less than 0.001). During the subsequent winter, without further immunisation, protection by the vaccine was no longer statistically significant. There was no clear correlation between clinical protection and either carriage of H influenzae or the level of antibody to H influenzae antigen in saliva.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867396     DOI: 10.1016/s0140-6736(85)92559-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  21 in total

1.  Cellular changes in the bronchoalveolar lavage (BAL) of pigs, following immunization by the enteral or respiratory route.

Authors:  S Delventhal; A Hensel; K Petzoldt; R Pabst
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 2.  Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.

Authors:  Edward Teo; Kathleen Lockhart; Sai Navya Purchuri; Jennifer Pushparajah; Allan W Cripps; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-06-19

Review 3.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

4.  Lymphocyte subsets in bronchoalveolar lavage after exposure to Actinobacillus pleuropneumoniae in pigs previously immunized orally or by aerosol.

Authors:  R Pabst; S Delventhal; A Gebert; A Hensel; K Petzoldt
Journal:  Lung       Date:  1995       Impact factor: 2.584

5.  Development of bronchus associated lymphoid tissue (BALT) in human lung disease: a normal host defence mechanism awaiting therapeutic exploitation?

Authors:  P G Holt
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

Review 6.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 7.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

8.  Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.

Authors:  Allan W Cripps; Keith Peek; Margaret Dunkley; Kevin Vento; Joanne K Marjason; Madonna E McIntyre; Phil Sizer; Duncan Croft; Lis Sedlak-Weinstein
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

9.  A role for intestinal T lymphocytes in bronchus mucosal immunity.

Authors:  F J Wallace; A W Cripps; R L Clancy; A J Husband; C S Witt
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

10.  Nontypeable Haemophilus influenzae: pathogenesis and prevention.

Authors:  A R Foxwell; J M Kyd; A W Cripps
Journal:  Microbiol Mol Biol Rev       Date:  1998-06       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.